We Can Medicines Co., Ltd. (TPEX:6929)
Taiwan · Delayed Price · Currency is TWD 30.80
-0.55 (-1.75%)
Jan 22, 2026, 12:38 PM CST
We Can Medicines Revenue
We Can Medicines had revenue of 789.55M TWD in the quarter ending September 30, 2025, a decrease of -2.84%. This brings the company's revenue in the last twelve months to 3.22B, down -1.47% year-over-year. In the year 2024, We Can Medicines had annual revenue of 3.27B with 4.69% growth.
Revenue (ttm)
3.22B
Revenue Growth
-1.47%
P/S Ratio
0.44
Revenue / Employee
3.20M
Employees
1,005
Market Cap
1.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.27B | 146.31M | 4.69% |
| Dec 31, 2023 | 3.12B | -179.84M | -5.45% |
| Dec 31, 2022 | 3.30B | 508.66M | 18.21% |
| Dec 31, 2021 | 2.79B | 127.32M | 4.77% |
| Dec 31, 2020 | 2.67B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Uni-President Enterprises | 673.00B |
| President Chain Store | 347.09B |
| Great Wall Enterprise | 101.66B |
| Standard Foods | 28.52B |
| Charoen Pokphand Enterprise (Taiwan) | 28.18B |
| TTET Union | 21.53B |
| Lian Hwa Foods | 12.95B |
| Hey Song | 9.58B |